Nuvation Bio (NUVB) Change in Interest Receivables (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Change in Interest Receivables of -$24000.0 for Q1 2026, down 101.62% year-over-year from $1.5 million in Q1 2025, and up 98.93% quarter-over-quarter from -$2.2 million in Q4 2025.
Powered by 
Analysis
Nuvation Bio (NUVB) Change in Interest Receivables (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Change in Interest Receivables for 7 consecutive years, with -$24000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Interest Receivables fell 101.62% year-over-year to -$24000.0; the TTM figure through Mar 2026 stood at -$1.8 million (down 332.73% YoY), while the FY2025 annual figure was -$285000.0, down 115.91% from the prior year.
- Change in Interest Receivables climbed to -$24000.0 in Q1 2026 per NUVB's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $1.5 million in Q3 2025 and bottomed at -$2.2 million in Q4 2025.
- Historically, Change in Interest Receivables has averaged $13058.8 across 5 years, with a median of $135000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Interest Receivables plunged 609.09% — and 2025, when it surged 529.8%.
- Nuvation Bio's Change in Interest Receivables stood at $135000.0 in 2022, then soared by 395.56% to $669000.0 in 2023, then tumbled by 185.05% to -$569000.0 in 2024, then sank by 294.02% to -$2.2 million in 2025, then surged by 98.93% to -$24000.0 in 2026.
- Business Quant data shows NUVB's Change in Interest Receivables at -$24000.0 in Q1 2026, -$2.2 million in Q4 2025, and $1.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn | 627,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 627,000.00 |
| Mar 31, 2026 | -24,000.00 |
| Dec 31, 2025 | -2.24 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Dec 31, 2024 | -569,000.00 |
| Sep 30, 2024 | 245,000.00 |
| Jun 30, 2024 | -389,000.00 |
| Mar 31, 2024 | 581,000.00 |
| Dec 31, 2023 | 669,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Jun 30, 2023 | 522,000.00 |
| Mar 31, 2023 | -212,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Sep 30, 2022 | -318,000.00 |
| Jun 30, 2022 | 175,000.00 |
| Mar 31, 2022 | -546,000.00 |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | -183,000.00 |